Extended Data Fig. 6. Impaired development of Nir3–/– OT-II transgenic T cells.
Bone marrow cells from CD45.1/CD45.2 Nir3 sufficient (WT) OT-II mice and CD45.2 Nir3–/– OT-II mice were mixed at 1:1 ratio and adoptively transferred into CD45.1 hosts. 6 weeks after the transfer, WT OT-II and Nir3–/– OT-II thymocytes at each development stage and splenic T cells were identified by congenic CD45 markers. The percentages of WT OT-II cells and Nir3–/– OT-II cells in each stage were quantified. TN, T naive; TEM, T effector memory-like. N = 8 mice. Data are shown as the mean ± s.e.m. and are pooled from 2 independent experiments. P values were determined using a two-tailed Student’s t-test.